Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (September 2023)
22 slides from Nemaura Medical's investor presentation, Sep 6, 2023
Slide 1: Corporate Presentation
Corporate Presentation 6th September 2023 Nasdaq: NMRD
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “int
Slide 3: What is the market space Nemaura is trying to address?
What is the market space Nemaura is trying to address?
Slide 4: A recent article in Forbes states: Over 11% of the US population is diabetic
A recent article in Forbes1 states: Over 11% of the US population is known to be diabetic; that translates into 37,300,000 people. Compounding the problem are approximately estimated 8,500,000 people who have diabetes but remain undiagnosed. People with diagnosed diabetes incur average medical expen
Slide 5: To address this, we developed a non-invasive daily wear continuous glucose sensor
To address this, we developed a Non-invasive daily wear continuous Glucose sensor targeting: Clinical Market: Type 2 diabetes: >60 million people in Europe2 Consumer market: Pre-diabetes and Obesity: >90 million people1 in USA [This market is currently deemed to be the largest opportunity for Nemaur
Slide 6: Our Goals and What we have delivered so far..
Our Goals and What we have delivered so far.. TARGET: Develop sugarBEAT® a wearable device form factor (see image on left). STATUS: Complete TARGET: Complete Pivotal clinical program and obtain CE approval STATUS: Complete TARGET: Receive first purchase order for sugarBEAT® STATUS: Complete – 200K s
Slide 7: Our Goals and What we have delivered so far..
Our Goals and What we have delivered so far.. TARGET: Develop a a Metabolic health and diabetes management program leveraging off sensor platform STATUS: Complete: BEATdiabetes.life & Miboko.com TARGET: Develop launch plans for BEAT®diabetes and Miboko. STATUS: Entered into preliminary agreement wit
Slide 8: Future targets..
Future targets.. TARGET: Obtain FDA approval for sugarBEAT® TARGET: Scale-up manufacture to support sales in UK, Europe & and Middle East through licensees TARGET: Build market share in USA with employers and insurers, for the BEAT®diabetes and Miboko (non-medical) programs. Scaled-up Pilot programs
Slide 9: sugarBEAT
sugarBEAT® Example of Volunteer data compared with BGM and Invasive CGM Blue: Finger Prick BGM (Blood glucose meter) sugarBEAT® Red: Invasive CGM Raw data presented (prior to algorithmic conversion, demonstrating tight correlation)
Slide 10: sugarBEAT
sugarBEAT® Example of Volunteer data (Non-diabetic)
Slide 11: Product Positioning
Product Positioning Medical: sell sugarBEAT® sensors Diabetes Management (non-medical): BEATdiabetes program and sensors Consumer health and wellbeing: Miboko sensor and app
Slide 12: Product Positioning – Medical
Product Positioning – Medical sugarBEAT® CGM sales through Licensee(s) – no further marketing spend required on Nemaura’s part thus minimizing cost of sales. Support UK Licensee: Licensee engaged in studies designed to support reimbursement from the UK government. Middle East: SFDA Approval achieved
Slide 13: Product Positioning – Type 2
Product Positioning – Type 2 Type 2 Diabetes management and reversal using BEATdiabetes program and sensors • Signed term sheet with Eversana who have a 6000+ salesforce, to sell the program B to B. • Aiming for reimbursement for T2 diabetes management
Slide 14: Product Positioning – Consumer
Product Positioning – Consumer Metabolic health and wellbeing: Miboko app • Phase 1 Beta running • Piloting with NHS in UK • Positive feedback thus far • Aiming for reimbursement for preventative medicine/high risk persons • Targeting partnership/collaborations in 2023
Slide 15: Marketing Strategy – Plug-in
Marketing Strategy – Plug-in Recent feedback suggests there is a significant business case to offer the Metabolic health program (from Miboko), and the proBEAT sensor and auto- generated progress report as plug-ins to existing diabetes management and metabolic health programs. In the USA alone there
Slide 16: Competitive landscape
Competitive landscape Noom: Over 50 million Subscribers, >$400m Revenues in 20205 Miboko USP: A holistic Metabolic health approach to weight loss and better health supported using our proprietary wearable sensor that gives an insight in to what’s really happening inside the body
Slide 17: sugarBEAT Regulatory Status
sugarBEAT® Regulatory Status § CE Approved Class 2b Medical Device in Europe § FDA PMA submitted and in review • FDA Bio-monitoring Division (BIMO) Audit conducted in December 2021 at Nemaura’s UK facility. A single 483 observation was issued. Company submitted a full and complete response to FDA in
Slide 18: Future Product Opportunities
Future Product Opportunities Leveraging the BEAT® Technology A rich portfolio of additional products to complement existing offering and contribute to increased revenues CONTINUOUS LACTATE MONITORING BODY TEMPERATURE MONITORING Assists in threshold maximization in Gives a more accurate and large dat
Slide 19: Future Product Opportunities
Future Product Opportunities Leveraging the BEAT® Technology ALCOHOL MONITORING DRUG MONITORING Support personal health goals and provide Monitoring the impact of drugs and personalized warnings prior to driving. treatment plan for patients. Provide physicians with individual’s drinking Global thera
Slide 20: Intellectual Property
Intellectual Property § IP consists of Filed Patents and substantial know-how
Slide 21: Summary
Summary § Revenue generating and ramp-up in revenues anticipated through product and subscription service sales and potential new partnerships § First mover advantage with the non-invasive sensor platform § Simple subscription-based revenue generation models. § Highly Scalable business model with po
Slide 22: References
References 1. https://www.forbes.com/sites/stephenbrozak/2022/11/07/diabetesthe-pandemic-is-here-how- do-we-treat-it/?sh=114c799b65be 2. https://www.who.int/europe/health-topics/diabetes#tab=tab_1 3. https://www.cdc.gov/diabetes/library/reports/reportcard/national-dpp.html
Nemaura Medical — Investor Presentation (September 2023) on 6ix